Cover Image
市場調查報告書

青光眼:全球醫藥品預測、市場分析

PharmaPoint: Glaucoma - Global Drug Forecast and Market Analysis to 2026

出版商 GlobalData 商品編碼 619856
出版日期 內容資訊 英文 280 Pages
訂單完成後即時交付
價格
Back to Top
青光眼:全球醫藥品預測、市場分析 PharmaPoint: Glaucoma - Global Drug Forecast and Market Analysis to 2026
出版日期: 2017年12月20日 內容資訊: 英文 280 Pages
簡介

本報告提供青光眼的上市藥及後期階段的開發平台候補藥的相關調查,青光眼概要,市場收益,目前治療選項、未滿足需求、機會,主要7個市場的處方藥的銷售額的影響的要素,開發平台分析,現在、未來的處方藥市場上競爭趨勢,市場主要促進因素、阻礙因素、課題等彙整資料。

第1章 目錄

第2章 摘要整理

第3章 簡介

第4章 疾病概要

  • 病因、病理學
  • 分類
  • 症狀
  • 預後、QOL

第5章 流行病學

  • 疾病的背景
  • 風險要素、合併症
  • 全球、過去趨勢
  • 預測手法
  • 青光眼的流行病學的預測
  • 討論

第6章 疾病管理

  • 診斷概要
  • 治療概要
  • 美國
  • EU5個國家
  • 日本

第7章 競爭評估

  • 概要
  • 產品簡介:領導品牌,前列腺素類似體
  • 產品簡介:領導品牌,固定劑量複方藥物
  • 產品簡介:β受體阻斷劑 (多數品牌)
  • 產品簡介:Alpha腎上腺素受體刺激藥
  • 產品簡介:碳酸酐酵素抑制劑物質
  • 產品簡介:膽鹼促效劑 (縮小瞳孔藥) (多數品牌)
  • 產品簡介:領導品牌,Rho激梅抑制劑

第8章 未滿足需求、機會的評估

  • 概要
  • 病人依從性的改善
  • 大幅度的眼壓下降功能的治療選項
  • 神經防護作用
  • 診斷、監測改善

第9章 開發平台評估

  • 概要
  • 臨床實驗製圖
  • 臨床開發中的潛力治療藥物
  • 早期階段開發中的潛力治療藥物
  • 開發中的其他治療藥物

第10章 現在、未來的企業

  • 概要
  • 企業策略趨勢
  • 企業簡介

第11章 市場展望

  • 全球市場
  • 美國
  • EU5個國家
  • 日本

第12章 附錄

目錄
Product Code: GDHC158PIDR

Glaucoma is the leading cause of irreversible vision loss, worldwide. The term glaucoma includes many different diseases, which are associated with differing risk factors, symptoms, treatment, and prognosis. All forms of glaucoma are characterized by the loss of the retinal ganglion cells and their axons that make up the optic nerve, which results in a cupping of the optic nerve head. This leads to optic nerve damage and visual field loss. Raised intraocular pressure (IOP) is the primary risk factor for glaucoma, and progression of disease will normally stop if the IOP is lowered by 30-50%. Consequently, treatment options for glaucoma are developed around lowering the IOP. Although it is possible to slow the progression of glaucoma using current treatment options, it is not possible to reverse vision loss that has resulted from the disease.

Most drugs prescribed for glaucoma can be placed into one of four drug classes. Prostaglandin analogues (PGAs) are generally used as a first-line treatment, with beta blockers (BBs), alpha adrenergic receptor agonists (AAs), and carbonic anhydrase inhibitors (CAIs) also frequently used, albeit generally as second-line therapies in combination with PGAs. Certain combinations of available drugs are marketed as part of fixed-dose combination (FDC) therapies. Cholinergic agonists, also known as miotics, can also be used for the treatment of glaucoma, although they are much less commonly prescribed compared with PGAs, BBs, AAs, and CAIs.

Scope

  • Overview of glaucoma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
  • Topline Glaucoma market revenue from 2016-2026. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
  • Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting glaucoma therapeutics sales in the 7MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global CDI therapeutics and prophylactics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global glaucoma therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the glaucoma therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 8
  • 1.2 List of Figures 11

2 Executive Summary 12

  • 2.1 Solid Growth Is Projected for the Glaucoma Market between 2016 and 2026 13
  • 2.2 The Development of Drugs with Novel MOAs Marks a Shift in Glaucoma Corporate Strategy 15
  • 2.3 Some Unmet Need Remains for Glaucoma, In Particular Improving Patient Compliance 16
  • 2.4 Opportunities Remain for Products that Further Address Unmet Needs in the Glaucoma Market 17
  • 2.5 Late-Stage Pipeline Drugs Entering the Glaucoma Market Are Poised to Drive Growth 18
  • 2.6 What Do Physicians Think? 20

3 Introduction 22

  • 3.1 Catalyst 22
  • 3.2 Related Reports 23
  • 3.3 Upcoming Related Reports 23

4 Disease Overview 24

  • 4.1 Introduction 24
  • 4.2 Etiology and Pathophysiology 25
    • 4.2.1 Etiology 25
    • 4.2.2 Pathophysiology 28
  • 4.3 Classification 32
  • 4.4 Symptoms 34
  • 4.5 Prognosis and Quality of Life 35

5 Epidemiology 36

  • 5.1 Disease Background 36
  • 5.2 Risk Factors and Comorbidities 37
  • 5.3 Global and Historical Trends 37
  • 5.4 Forecast Methodology 40
    • 5.4.1 Sources 40
    • 5.4.2 Forecast Assumptions and Methods 44
    • 5.4.3 Total Prevalent Cases of POAG 44
    • 5.4.4 Total Prevalent Cases of PACG 46
    • 5.4.5 Total Prevalent Cases of NTG and PPG 48
    • 5.4.6 Total Prevalent Cases of SG 49
    • 5.4.7 Diagnosed Prevalent Cases 50
    • 5.4.8 Diagnosed Incident Cases of Acute PACG 51
  • 5.5 Epidemiological Forecast for Glaucoma (2016-2026) 52
    • 5.5.1 Total Prevalent Cases of POAG 52
    • 5.5.2 Age-Specific Total Prevalent Cases of POAG 53
    • 5.5.3 Sex-Specific Total Prevalent Cases of POAG 54
    • 5.5.4 Diagnosed Prevalent Cases of POAG 55
    • 5.5.5 Total Prevalent Cases of PACG 56
    • 5.5.6 Age-Specific Total Prevalent Cases of PACG 57
    • 5.5.7 Sex-Specific Total Prevalent Cases of PACG 58
    • 5.5.8 Diagnosed Prevalent Cases of PACG 59
    • 5.5.9 Total Prevalent Cases of NTG 60
    • 5.5.10 Diagnosed Prevalent Cases of NTG 61
    • 5.5.11 Total Prevalent Cases of PPG 62
    • 5.5.12 Diagnosed Prevalent Cases of PPG 63
    • 5.5.13 Total Prevalent Cases of SG 64
    • 5.5.14 Diagnosed Prevalent Cases of SG 65
    • 5.5.15 Diagnosed Incident Cases of Acute PACG 66
  • 5.6 Discussion 67
    • 5.6.1 Epidemiological Forecast Insight 67
    • 5.6.2 Limitations of the Analysis 67
    • 5.6.3 Strengths of the Analysis 68

6 Disease Management 69

  • 6.1 Diagnosis Overview 69
  • 6.2 Treatment Overview 72
    • 6.2.1 Treatment Guidelines 74
    • 6.2.2 Leading Prescribed Drugs 75
    • 6.2.3 Clinical Practice 75
  • 6.3 US 77
  • 6.4 5EU 79
  • 6.5 Japan 81

7 Competitive Assessment 84

  • 7.1 Overview 84
  • 7.2 Product Profiles - Major Brands, Prostaglandin Analogues 84
    • 7.2.1 Xalatan (latanoprost) 85
    • 7.2.2 Lumigan (bimatoprost) 90
    • 7.2.3 Travatan (travoprost) 96
    • 7.2.4 Tapros (tafluprost) 99
    • 7.2.5 Vyzulta (latanoprostene bunod) 104
  • 7.3 Product Profiles, Fixed-Dose Combination Therapies 110
    • 7.3.1 Overview 110
    • 7.3.2 Efficacy 114
    • 7.3.3 Safety 115
    • 7.3.4 Forecast 115
  • 7.4 Product Profiles, Beta Blockers (numerous brands) 115
    • 7.4.1 Overview 115
    • 7.4.2 Efficacy 118
    • 7.4.3 Safety 118
    • 7.4.4 Forecast 119
  • 7.5 Product Profiles, Alpha-Adrenergic Agonists (numerous brands) 119
    • 7.5.1 Overview 119
    • 7.5.2 Efficacy 121
    • 7.5.3 Safety 121
    • 7.5.4 Forecast 121
  • 7.6 Product Profiles, Carbonic Anhydrase Inhibitors (numerous brands) 122
    • 7.6.1 Overview 122
    • 7.6.2 Efficacy 123
    • 7.6.3 Safety 124
    • 7.6.4 Forecast 125
  • 7.7 Product Profiles, Cholinergic Agonists (Miotics) (numerous brands) 125
    • 7.7.1 Overview 125
    • 7.7.2 Efficacy 126
    • 7.7.3 Safety 127
    • 7.7.4 Forecast 127
  • 7.8 Product Profiles - Major Brands, Rho Kinase Inhibitors 127
    • 7.8.1 Glanatec (ripasudil) 127

8 Unmet Needs and Opportunity Assessment 132

  • 8.1 Overview 132
  • 8.2 Improved Patient Compliance 134
    • 8.2.1 Unmet Need 134
    • 8.2.2 Gap Analysis 135
    • 8.2.3 Opportunity 136
  • 8.3 Treatment Options with Greater IOP-Lowering Ability 139
    • 8.3.1 Unmet Need 139
    • 8.3.2 Gap Analysis 140
    • 8.3.3 Opportunity 141
  • 8.4 Neuroprotective Drugs 142
    • 8.4.1 Unmet Need 142
    • 8.4.2 Gap Analysis 143
    • 8.4.3 Opportunity 144
  • 8.5 Improved Diagnosis and Monitoring 145
    • 8.5.1 Unmet Need 145
    • 8.5.2 Gap Analysis 146
    • 8.5.3 Opportunity 146

9 Pipeline Assessment 148

  • 9.1 Overview 148
  • 9.2 Clinical Trial Mapping 150
    • 9.2.1 Clinical Trials by Class, Development Phase and Region 150
  • 9.3 Promising Drugs in Clinical Development 151
    • 9.3.1 Rhopressa (netarsudil mesylate) 154
    • 9.3.2 Roclatan (netarsudil mesylate + latanoprost) 161
    • 9.3.3 Bimatoprost SR 167
    • 9.3.4 OTX-TP 172
    • 9.3.5 DE-117 177
    • 9.3.6 SJP-0135 181
  • 9.4 Promising Drugs in Early-Stage Development 184
    • 9.4.1 ENV-515 184
    • 9.4.2 Latanoprost SR Products 185
  • 9.5 Other Drugs in Development 187

10 Current and Future Players 188

  • 10.1 Overview 188
  • 10.2 Trends in Corporate Strategy 191
  • 10.3 Company Profiles 193
    • 10.3.1 Allergan 193
    • 10.3.2 Alcon (Novartis) 194
    • 10.3.3 Santen 195
    • 10.3.4 Pfizer 197
    • 10.3.5 Otsuka 198
    • 10.3.6 Valeant 199
    • 10.3.7 Aerie Pharmaceuticals 200
    • 10.3.8 Ocular Therapeutix 201

11 Market Outlook 203

  • 11.1 Global Markets 203
    • 11.1.1 Forecast 203
    • 11.1.2 Drivers and Barriers - Global Issues 207
  • 11.2 US 207
    • 11.2.1 Forecast 207
    • 11.2.2 Key Events 210
    • 11.2.3 Drivers and Barriers 211
  • 11.3 5EU 211
    • 11.3.1 Forecast 211
    • 11.3.2 Key Events 214
    • 11.3.3 Drivers and Barriers 215
  • 11.4 Japan 215
    • 11.4.1 Forecast 215
    • 11.4.2 Key Events 218
    • 11.4.3 Drivers and Barriers 219

12 Appendix 220

  • 12.1 Bibliography 220
  • 12.2 Abbreviations 246
  • 12.3 Methodology 249
    • 12.3.1 Forecasting Methodology 249
    • 12.3.2 Diagnosed Patients 249
    • 12.3.3 Percent Drug-Treated Patients 250
    • 12.3.4 Drugs Included in Each Therapeutic Class 250
    • 12.3.5 Launch and Patent Expiry Dates 251
    • 12.3.6 General Pricing Assumptions 252
    • 12.3.7 Individual Drug Assumptions 253
    • 12.3.8 Generic Erosion 268
    • 12.3.9 Pricing of Pipeline Agents 268
  • 12.4 Primary Research - KOLs Interviewed for This Report 270
  • 12.5 Primary Research - Payers Interviewed for This Report 273
  • 12.6 Primary Research - Prescriber Survey 274
  • 12.7 About the Authors 275
    • 12.7.1 Analysts 275
    • 12.7.2 Therapy Area Director 275
    • 12.7.3 Epidemiologist 276
    • 12.7.4 Managing Epidemiologists 276
    • 12.7.5 Global Director of Therapy Analysis and Epidemiology 277
    • 12.7.6 Global Head of Healthcare 278
  • 12.8 About GlobalData 279
  • 12.9 Contact Us 279
  • 12.10 Disclaimer 280

List of Tables

  • Table 1: Glaucoma: Key Metrics in the 7MM 12
  • Table 2: Symptoms of Glaucoma 35
  • Table 3: Risk Factors and Comorbidities for Glaucoma 37
  • Table 4: 7MM, Total Prevalent Cases of POAG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026 52
  • Table 5: 7MM, Diagnosed Prevalent Cases of POAG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026 55
  • Table 6: 7MM, Total Prevalent Cases of PACG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026 56
  • Table 7: 7MM, Diagnosed Prevalent Cases of PACG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026 59
  • Table 8: 7MM, Total Prevalent Cases of NTG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026 60
  • Table 9: 7MM, Diagnosed Prevalent Cases of NTG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026 61
  • Table 10: 7MM, Total Prevalent Cases of PPG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026 62
  • Table 11: 7MM, Diagnosed Prevalent Cases of PPG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026 63
  • Table 12: 7MM, Total Prevalent Cases of SG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026 64
  • Table 13: 7MM, Diagnosed Prevalent Cases of SG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026 65
  • Table 14: 7MM, Diagnosed Incident Cases of Acute PACG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026 66
  • Table 15: Diagnostic Tests for Glaucoma 69
  • Table 16: Drug Classes Used to Treat Glaucoma 73
  • Table 17: Treatment Guidelines for Glaucoma 74
  • Table 18: Most-Prescribed Drugs for Glaucoma by Class in the 7MM, 2016 75
  • Table 19: Country Profile - US 79
  • Table 20: Country Profile - 5EU 81
  • Table 21: Country Profile - Japan 83
  • Table 22: Product Profile - Xalatan 87
  • Table 23: Observed Clinical Efficacy of Xalatan in a Phase IV Trial 87
  • Table 24: Number of Treatment-Related AEs in a Phase IV Trial for Xalatan 88
  • Table 25: Xalatan SWOT Analysis, 2017 89
  • Table 26: Product Profile - Lumigan 92
  • Table 27: Results from a Phase IV Clinical Trial Comparing the Change in IOP After One Year In Patients Taking Lumigan, Xalatan, or Travatan 92
  • Table 28: Comparison of Results from Two Phase IV Clinical Trials Assessing the Change in IOP In Patients Who Receive One of Two Doses Of Lumigan 93
  • Table 29: Comparison of Reported AEs from Patients Receiving Lumigan 0.01% and Lumigan 0.03% 94
  • Table 30: Lumigan SWOT Analysis, 2017 95
  • Table 31: Product Profile - Travatan 97
  • Table 32: Travatan SWOT Analysis, 2017 98
  • Table 33: Product Profile - Tapros 101
  • Table 34: Reduction in IOP Observed in a Phase IV Trial Comparing Tapros and Xalatan 102
  • Table 35: Tapros AEs 102
  • Table 36: Tapros SWOT Analysis, 2017 103
  • Table 37: Product Profile - Vyzulta 106
  • Table 38: Observed Clinical Efficacy of Vyzulta in Two Phase III Trials 107
  • Table 39: Safety Profile of Vyzulta Observed in the LUNAR Phase III Trial 108
  • Table 40: Vyzulta SWOT Analysis, 2017 109
  • Table 41: FDCs Available in the 7MM 114
  • Table 42: Beta Blockers Available in the 7MM 116
  • Table 43: AA Monotherapies Available in the 7MM 120
  • Table 44: CAIs Available in the 7MM 122
  • Table 45: Results from a Phase III Clinical Trial Comparing the Change in IOP in Glaucoma Patients After Administration of Azopt, Trusopt, or Timolol 124
  • Table 46: Frequently Reported AEs During a Phase III Clinical Trial Comparing Azopt, Trusopt, and Timolol 125
  • Table 47: Cholinergic Agonists Available in the 7MM 126
  • Table 48: Product Profile - Glanatec 129
  • Table 49: Results from Two Phase III Clinical Trials Comparing the Change in IOP When Glanatec Is Used Adjunctively with Timolol or Xalatan 130
  • Table 50: Frequently Reported AEs During Two Phase III Clinical Trials Assessing the Safety and Efficacy of Glanatec When Used Adjunctively with Timolol or Xalatan 130
  • Table 51: Glanatec SWOT Analysis, 2017 131
  • Table 52: Promising Products in Late-Stage Clinical Development for Treatment of Glaucoma 152
  • Table 53: Product Profile - Rhopressa 157
  • Table 54: Most Frequently Observed AEs for Rhopressa and Timolol in Rocket-4 Phase III Trial 158
  • Table 55: Rhopressa SWOT Analysis, 2017 160
  • Table 56: Product Profile - Roclatan 163
  • Table 57: Mean Diurnal IOP Change over 90 days of Treatment with Roclatan Compared With Latanoprost and Rhopressa 164
  • Table 58: Common AEs Observed in the Mercury-1 and Mercury-2 Phase III Trials 164
  • Table 59: Roclatan SWOT Analysis, 2017 166
  • Table 60: Product Profile - Bimatoprost SR 169
  • Table 61: Data Presented from a Phase II Trial Comparing the Efficacy of Bimatoprost SR with Topical Bimatoprost 0.3% 169
  • Table 62: Bimatoprost SR SWOT Analysis, 2017 171
  • Table 63: Product Profile - OTX-TP 173
  • Table 64: Reduction in Diurnal IOP from Baseline Following Treatment with OTX-TP and Timolol 174
  • Table 65: OTX-TP SWOT Analysis, 2017 176
  • Table 66: Product Profile - DE-117 178
  • Table 67: AEs Reported in the Different Arms of Phase II Clinical Trials of DE-117 179
  • Table 68: DE-117 SWOT Analysis, 2017 181
  • Table 69: Product Profile - SJP-0135 182
  • Table 70: SJP-0135 SWOT Analysis, 2017 184
  • Table 71: Developmental Phase II Latanoprost SR Products for the Treatment of Glaucoma 186
  • Table 72: Drugs in Development for Glaucoma, 2017 187
  • Table 73: Key Companies in the Glaucoma Market in the 7MM, 2017 189
  • Table 74: Allergan's Glaucoma Portfolio Assessment, 2017 194
  • Table 75: Alcon's Glaucoma Portfolio Assessment, 2017 195
  • Table 76: Santen's Glaucoma Portfolio Assessment, 2017 197
  • Table 77: Pfizer's Glaucoma Portfolio Assessment, 2017 198
  • Table 78: Otsuka's Glaucoma Portfolio Assessment, 2017 199
  • Table 79: Valeant's Glaucoma Portfolio Assessment, 2017 200
  • Table 80: Aerie Pharmaceuticals' Glaucoma Portfolio Assessment, 2017 201
  • Table 81: Ocular Therapeutics' Glaucoma Portfolio Assessment, 2017 202
  • Table 82: Global Sales Forecast ($M) for Glaucoma by Product, 2016-2026 204
  • Table 83: Glaucoma Market - Global Drivers and Barriers, 2016-2026 207
  • Table 84: Key Events Impacting Sales for Glaucoma in the US, 2016-2026 210
  • Table 85: Glaucoma Market - Drivers and Barriers in the US, 2016-2026 211
  • Table 86: Key Events Impacting Sales for Glaucoma in the 5EU, 2016-2026 214
  • Table 87: Glaucoma Market - Drivers and Barriers in the 5EU, 2016-2026 215
  • Table 88: Key Events Impacting Sales for Glaucoma in Japan, 2016-2026 218
  • Table 89: Glaucoma Market - Drivers and Barriers in Japan, 2016-2026 219
  • Table 90: Sources Used For Diagnosed Glaucoma Incidence and Segmentation in the 7MM 250
  • Table 91: Projected Launch Dates for Glaucoma 251
  • Table 92: Key Historical and Projected Patent Expiry Dates for Glaucoma 252
  • Table 93: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 274

List of Figures

  • Figure 1: Global Sales Forecast by Country for Glaucoma in 2016 and 2026 14
  • Figure 2: Analysis of the Company Portfolio Gap in Glaucoma During the Forecast Period 16
  • Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of Glaucoma During the Forecast Period 19
  • Figure 4: The Flow of AqH in an Eye with OAG and ACG 26
  • Figure 5: The Different Causes of Secondary Glaucoma 27
  • Figure 6: The Aqueous Humor Cycle 29
  • Figure 7: Nerve Damage - Cupping 30
  • Figure 8: Different Classifications of Glaucoma 33
  • Figure 9: 7MM, Age-Standardized Total Prevalence of POAG, Men and Women, Ages ≥40 Years, 2016 38
  • Figure 10: 7MM, Age-Standardized Total Prevalence of PACG, Men and Women, Ages ≥40 Years, 2016 39
  • Figure 11: 7MM, Sources Used to Forecast Total Prevalent Cases of POAG 40
  • Figure 12: 7MM, Sources Used to Forecast Total Prevalent Cases of PACG 41
  • Figure 13: 7MM, Sources Used to Forecast Total Prevalent Cases of NTG 42
  • Figure 14: 7MM, Sources Used to Forecast Total Prevalent Cases of PPG 42
  • Figure 15: 7MM, Sources Used to Forecast Total Prevalent Cases of SG 43
  • Figure 16: 7MM, Sources Used to Forecast Diagnosed Incident Cases of Acute PACG 43
  • Figure 17: 7MM, Age-Specific Total Prevalent Cases of POAG, Both Sexes, Ages ≥40 Years, N, 2016 53
  • Figure 18: 7MM, Sex-Specific Total Prevalent Cases of POAG, Both Sexes, Ages ≥40 Years, N, 2016 54
  • Figure 19: 7MM, Age-Specific Total Prevalent Cases of PACG, Both Sexes, Ages ≥40 Years, N, 2016 57
  • Figure 20: 7MM, Sex-Specific Total Prevalent Cases of PACG, Both Sexes, Ages ≥40 Years, N, 2016 58
  • Figure 21: Glaucoma Clinical Treatment Flowchart 77
  • Figure 22: Drug Launch and Patent Expiration Timelines of PGAs for Glaucoma in the 7MM 85
  • Figure 23: Drug Launch and Patent Expiration Timelines of FDCs for Glaucoma in the 7MM 111
  • Figure 24: Unmet Need and Opportunity in Glaucoma, 2017 133
  • Figure 25: Bullseye Diagram of Products in Clinical Development for Glaucoma, 2017 149
  • Figure 26: Number of Ongoing Phase I-III Clinical Trials in Various Drug Classes for Glaucoma in the 7MM as of September 2017 150
  • Figure 27: Regional Shares of Ongoing Glaucoma Clinical Trials in the 7MM 151
  • Figure 28: Key Phase III Trials for the Promising Pipeline Agents that GlobalData Expects be Licensed for Glaucoma in the 7MM During the Forecast Period 153
  • Figure 29: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of Glaucoma During the Forecast Period 154
  • Figure 30: Clinical and Commercial Positioning of Rhopressa 159
  • Figure 31: Clinical and Commercial Positioning of Roclatan 165
  • Figure 32: Clinical and Commercial Positioning of Bimatoprost SR 170
  • Figure 33: Clinical and Commercial Positioning of OTX-TP 175
  • Figure 34: Clinical and Commercial Positioning of DE-117 180
  • Figure 35: Clinical and Commercial Positioning of SJP-0135 183
  • Figure 36: Global Sales of Branded Products for Glaucoma by Company in 2016 and 2026 190
  • Figure 37: Analysis of the Company Portfolio Gap in Glaucoma During the Forecast Period 191
  • Figure 38: Global (7MM) Sales Forecast by Country for Glaucoma in 2016 and 2026 206
  • Figure 39: Sales Forecast by Class for Glaucoma in the US in 2016 and 2026 209
  • Figure 40: Sales Forecast by Class for Glaucoma in the 5EU in 2016 and 2026 213
  • Figure 41: Sales Forecast by Class for Glaucoma in Japan in 2016 and 2026 217
Back to Top